Recent developments for Nanobiotix include key share acquisition transactions, clarifications on takeover speculations, and progress in clinical trials for oncology drug candidates.

• Nanobiotix announced key share acquisition transactions in early April 2026 [N1].
• The company clarified recent media speculations regarding a potential takeover in March 2026 [N2].
• Nanobiotix revealed favorable results from the JNJ-1900 study in pancreatic cancer and is seeking further evaluation as of May 2025 [N5].
• Dosing began in a mid-stage NSCLC study, with the first patient dosed in the Phase 2 study of JNJ-1900 for NSCLC in January 2025 [N6][N7].
• The company was highlighted among stocks delivering significant gains in 2025, with a 660% increase noted in November 2025 [N4].

Nanobiotix has demonstrated clinical progress with favorable results in pancreatic cancer studies and active dosing in NSCLC trials, indicating potential for future therapeutic approvals. The company’s ability to secure share acquisition transactions and clarify market rumors suggests active corporate management and investor engagement. Its liquidity position supports ongoing operations and clinical development. Positive market recognition, including significant stock gains in 2025, reflects investor interest in its pipeline and growth prospects.

Nanobiotix reported a net loss of €23.96 million for the fiscal year ended 2025, indicating ongoing operational expenses exceeding revenues. The company remains dependent on clinical trial outcomes, which carry scientific and regulatory uncertainties. Liquidity ratios near 1.0 suggest limited buffer against short-term liabilities, potentially constraining financial flexibility. Market speculation about takeovers introduces uncertainty regarding corporate control and strategic direction. The biotechnology sector’s inherent risks, including competition and regulatory hurdles, also apply.

Nanobiotix's moat is primarily based on its proprietary oncology drug candidates and clinical trial progress. The company’s focus on innovative cancer therapies, including JNJ-1900, positions it within a specialized niche of the biotechnology sector. Its regulatory filings and clinical data disclosures contribute to transparency and investor confidence. However, as a clinical-stage biotech firm, its competitive advantage depends heavily on successful trial outcomes and regulatory approvals, which are subject to inherent scientific and regulatory risks.

• Clinical Trial Risk: The company’s future depends on successful clinical trial outcomes for its oncology drug candidates, which are inherently uncertain and subject to regulatory approval processes.
• Financial Risk: Nanobiotix reported net losses and maintains liquidity ratios close to 1.0, indicating limited short-term financial cushion which may impact operational flexibility.
• Market and Corporate Risk: Speculation about potential takeovers and share acquisition transactions may introduce uncertainty regarding company control and strategic direction.

• Nanobiotix S.A. is a biotechnology company with ongoing clinical studies, including a Phase 2 study of JNJ-1900 for non-small cell lung cancer (NSCLC).
• The company reported favorable results from a JNJ-1900 study in pancreatic cancer and is seeking further evaluation.
• Nanobiotix has initiated dosing in a mid-stage NSCLC study and dosed the first patient in the Phase 2 study of JNJ-1900 for NSCLC.
• The company announced key share acquisition transactions in early 2026.
• Nanobiotix clarified recent media speculations regarding a potential takeover in March 2026.
• Financial figures as of December 31, 2025, include revenue of €32.6 million, a net loss of €23.96 million, and basic and diluted EPS of -€0.5 per share.
• Liquidity ratios as of December 31, 2025, show a current ratio of 1.09 and a cash ratio of 0.92, with cash and equivalents of €52.75 million and current liabilities of €57.5 million.
• The company files annual reports on Form 20-F and periodic reports on Form 6-K with the SEC.
• Nanobiotix's stock price was reported at $30.87 as of March 31, 2026.
• The company has been highlighted in news for significant stock gains in 2025, including a 660% increase during the year.